Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Caredx (CDNA) stock in plain English

Free brief · no signupStart here
CDNAPublished Nov 19, 2026
Caredx Inc
Healthcare · Diagnostics & Research
Sells blood-based genomic tests and digital solutions that detect organ transplant rejection risk without invasive biopsies.
Assets:
AlloSure testing platformMeasures donor-derived cell-free DNA to monitor kidney and heart transplant injury.
AlloMap gene expression testAnalyzes immune activity through RNA expression to evaluate heart transplant rejection risk.
KOAR registry studyMaintains a multi-center observational registry tracking thousands of kidney transplant patients over time.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

86
OPS ScoreOperating finances
Latest quote
-3.39%$71.92
$3.78B
30.0×
$497.22M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 19, 2026Quotes updated Nov 20, 04:00 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was CDNA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Caredx (CDNA) do?

Caredx Inc (CDNA) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells blood-based genomic tests and digital solutions that detect organ transplant rejection risk without invasive biopsies. It is worth $3.78B on the market and sold $497.22M over the last year.

Market cap
$3.78B
P/E ratio
30.0×
Annual sales
$497.22M
Sector
Healthcare
Industry
Diagnostics & Research
Brief updated
Nov 19, 2026

Brands and businesses behind CDNA

  • AlloSure: Measures donor cell-free DNA in blood samples to monitor transplant rejection, earning revenue from diagnostic service fees.
  • AlloMap: Evaluates gene expression to assess immune rejection in heart recipients, generating revenue through specialized lab service reimbursements.
  • HeartCare: Combines gene expression and cell-free DNA testing to monitor heart transplant recipients, earning diagnostic service billing revenue.
  • TransplantCare: Provides digital workflow and patient management software to transplant clinics, generating recurring software and service revenue.

CDNA’s flags, in plain English

Each flag is a number from Caredx’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 19, 2026.

Low debt

Low debt, only 6% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 70.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Earnings Jumping

Profits up 206.7% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.

Heavily Shorted

15% of tradable shares are bet against (sold short). A large share of the stock has been borrowed and sold by traders betting it will fall. That can be a warning, and it can also push the price up fast if they rush to buy it back.

2 more green flags open with the free trial. Try it free for 7 days.

Questions about CDNA

How big is Caredx?

Caredx’s market cap is $3.78B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $497.22M: what customers paid the company over the last year, before any costs.

What is CDNA’s P/E ratio?

CDNA’s P/E ratio is 30.0×. Investors pay about 30.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with CDNA?

Medicare and private insurer reimbursement policies for molecular diagnostic surveillance tests face ongoing scrutiny and periodic coverage restrictions. That is one risk on Caredx’s card. Its first risk flag is Heavily Shorted, explained above. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Caredx’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. CDNA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card